Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods - Global Medical Solutions Australia Pty Limited

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, addresses the regulation of therapeutic goods to ensure their safety, quality, and efficacy. This Act aims to protect public health by establishing a robust framework for the control and oversight of therapeutic goods. In alignment with its policy objective to facilitate the safe and effective use of therapeutic goods, the Act includes provisions for the licensing of manufacturers. As part of this regulatory process, the Therapeutic Goods Administration publishes details of licences granted to manufacturers, such as the recent grant to Global Medical Solutions Australia Pty Limited. This notification serves to inform the public and stakeholders of the entities authorised to manufacture therapeutic goods, thereby contributing to the overarching goal of safeguarding the therapeutic goods market.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, providing a comprehensive framework to ensure that these products are safe, of high quality, and effective. This Act applies to various entities, including individuals and companies, that are involved in the manufacturing, import, supply, advertising, or sponsorship of therapeutic goods within Australia. Therapeutic goods encompass a wide range of products such as medicines, medical devices, blood and blood components, tissues, and cosmetics. The Act's jurisdictional reach is national, applying across the Commonwealth of Australia, including states and territories. However, certain therapeutic goods, such as complementary medicines and some medical devices, may also be subject to state and territory laws. Exclusions and exemptions within the Act pertain to specific categories of goods, including those exempt from licensing requirements under certain conditions or where they fall under specific thresholds. The Therapeutic Goods Administration, an agency of the Department of Health, has the authority to extend or restrict the application of the Act through subordinate instruments, ensuring a flexible and responsive regulatory environment. This allows for the incorporation of new scientific evidence, technological advancements, and public health needs into the regulatory framework.

Key Provisions

The Therapeutic Goods Act 1989, under Section 38, allows for the Secretary to grant a licence to manufacture therapeutic goods to eligible parties. In this instance, the Secretary has granted such a licence to Global Medical Solutions Australia Pty Limited, identified as having the Licence Number MI-2014-LI-06500-1, and based at Building 57 Research Road at The University of Queensland, Queensland, 4072. This licence authorises the company to manufacture therapeutic goods, subject to compliance with all relevant regulations and standards set forth by the Therapeutic Goods Administration (TGA). Entities that receive a manufacturing licence under the Therapeutic Goods Act 1989 are required to adhere to stringent quality control measures and regulatory standards to ensure the safety and efficacy of the therapeutic goods they produce. These obligations include maintaining accurate records of all manufacturing processes, complying with Good Manufacturing Practice (GMP) standards, and ensuring that all products meet the required specifications as outlined in the Australian Register of Therapeutic Goods (ARTG). Furthermore, licence holders must submit regular reports to the TGA and allow for inspections of their facilities and processes to ensure ongoing compliance with the Act. Failure to comply with the requirements of the Therapeutic Goods Act 1989 or the conditions of the manufacturing licence can result in severe consequences. Under Section 42A, the TGA may cancel a licence if it is found that the licence holder has engaged in activities that are detrimental to public health or safety. Additionally, Section 42F imposes penalties for non-compliance, which may include fines up to a maximum of $1,260,000 for corporations and lesser amounts for individuals, depending on the severity of the offence. Criminal charges may also be brought against individuals or companies found to have knowingly contravened the Act, leading to potential imprisonment terms.